Equities
  • Price (EUR)125.22
  • Today's Change2.18 / 1.77%
  • Shares traded0.00
  • 1 Year change+0.02%
  • Beta--
Data delayed at least 15 minutes, as of Mar 21 2023 07:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Agilent Technologies, Inc. is engaged in providing application-focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. It operates in the life sciences, diagnostics and applied chemical markets. Its life sciences and applied markets business offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Its diagnostics and genomics businesses are comprised of six areas of activity, providing active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software, and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. Its product categories include liquid chromatography systems and components and liquid chromatography mass spectrometry systems.

  • Revenue in USD (TTM)6.93bn
  • Net income in USD1.32bn
  • Incorporated1999
  • Employees18.30k
  • Location
    Agilent Technologies Inc5301 Stevens Creek BlvdSANTA CLARA 95051United StatesUSA
  • Phone+1 (408) 345-8296
  • Fax+1 (408) 345-8474
  • Websitehttps://www.agilent.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
A:NYQ since
announced
Transaction
value
E-Msion IncDeal completed09 Mar 202309 Mar 2023Deal completed-2.76%--
Avida Biomed IncDeal completed04 Jan 202304 Jan 2023Deal completed-8.68%--
PSS Polymer Standards Service GmbHDeal completed02 Aug 202202 Aug 2022Deal completed2.68%--
Data delayed at least 15 minutes, as of Mar 21 2023 20:10 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.